Acquired cystic kidney disease: A benign yet potentially fatal condition

Abstract is not required for Clinical Imagesis not required for Clinical Images (This page in not part of the published article.) International Journal of Case Reports and Images, Vol. 8 No.8, August 2017. ISSN – [0976-3198] Int J Case Rep Images 2017;8(8):561–563. www.ijcasereportsandimages.com Bhatti et al. 561 CASE REPORT OPEN ACCESS Acquired cystic kidney disease: A benign yet potentially fatal condition Vikrampal Bhatti, Abhilash Koratala, Ashutosh M. Shukla


CASE REPORT OPEN ACCESS
Acquired cystic kidney disease: A benign yet potentially fatal condition Vikrampal Bhatti, Abhilash Koratala, Ashutosh M. Shukla

CASE REPORT
A 48-year-old African-American male with end stage renal disease (ESRD) on hemodialysis for 14 years developed acute abdominal pain during his outpatient dialysis session and was sent to the emergency room. The patient was found to be hypotensive with a blood pressure of 93/72 mmHg requiring fluid resuscitation, which later deteriorated further requiring vasopressors. He was found to have acute anemia with a hemoglobin level of 7.5 g/ dL. Abdominal computed tomography (CT) scan revealed large hemoperitoneum with a right perinephric sentinel clot, bilateral multiple renal cysts and features suspicious of bleeding originating from the upper anterior pole of right kidney (Figure 1). The largest of the cysts measured ~3.2 cm in diameter. Renal angiogram showed active ongoing extravasation from multiple branches of the right renal artery ( Figure 2). Selective right renal artery embolization was unsuccessful. An emergent laparotomy revealed a torn right renal capsule with subcapsular hemorrhage and a 1.4 cm ragged defect in the inferior portion of the kidney. He underwent right nephrectomy and pathology was negative for malignancy. It essentially showed end stage kidney with arteriolonephrosclerosis, tubular atrophy, interstitial fibrosis, thyroidization, cysts and chronic interstitial inflammation with associated intra-parenchymal and perirenal hemorrhage. Patient refused blood transfusion because of religious reasons and unfortunately died of hemorrhagic shock after the surgery.

DISCUSSION
Acquired cystic kidney disease (ACKD) in patients with advanced chronic kidney disease (CKD) and end  stage renal disease, unlike other forms of cystic renal diseases, is largely considered a benign pathology with no clear recommendations for follow-up care. Our case represents a rare but fatal complication of ACKD. Definition of ACKD usually requires three or more cysts in each kidney in a patient with CKD or end stage renal disease who does not have a hereditary cause of cystic disease such as autosomal-dominant polycystic kidney disease or tuberous sclerosis [1]. It is estimated that hemorrhagic cysts are seen in approximately 50% of the patients with ACKD and perinephric hematomas in about 13% of patients [2], which can generally be managed conservatively. Severe bleeding can be fatal and may require interventions such as transcatheter embolization or surgery. More studies are needed to determine the benefit of periodic screening in patients with ACKD to prevent potentially fatal complications.
Without clear guidelines for follow-up and majority of the studies on cystic renal diseases excluding patients with ACKD, the true incidence of complications in these patients is not known. We believe an observational cohort study on the lines of Bosniak classification, in patients with advanced CKD and end stage renal disease should be considered such that natural history of this condition, including potential complications e.g. malignancy [3] and bleeding can be better predicted.

CONCLUSION
Acquired cystic kidney disease (ACKD) is characterized by development of numerous cysts in both the kidneys in individuals without history of hereditary cystic disease. Hemorrhagic cysts can sometimes lead to severe bleeding that can be life-threatening. High index of suspicion is required for this condition when end stage renal disease patients present with abdominal pain and drop in hemoglobin. Until clear guidelines are established, it would be prudent to monitor ACKD patients with periodic renal imaging.

Edorium Journals: An introduction
Why should you publish with Edorium Journals?
In less than 10 words: "We give you what no one does".

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial review
All manuscripts submitted to Edorium Journals undergo pre-processing review followed by multiple rounds of stringent editorial reviews.

Peer review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early view version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates about status of your manuscripts.

Favored author program
One email is all it takes to become our favored author. You will not only get 15% off on all manuscript but also get information and insights about scholarly publishing.

Institutional membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in publication fees.

Our presence
We have high quality, attractive and easy to read publication format. Our websites are very user friendly and enable you to use the services easily with no hassle.
We request you to have a look at our website to know more about us and our services. Please visit: www.edoriumjournals.com We welcome you to interact with us, share with us, join us and of course publish with us.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

Six weeks
We give you our commitment that you will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this commitment by even one day, we will give you a 75% Discount Voucher for your next manuscript.

Four weeks
We give you our commitment that after we receive your page proofs, your manuscript will be published in the journal within 14 days (2 weeks). If we fail to honor this commitment by even one day, we will give you a 75% Discount Voucher for your next manuscript.